Dechra Pharmaceuticals Plc
Industry Group: Pharmaceuticals
Country/Region: United Kingdom
Identifier: -
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 19 out of 921
Universe
Global Universe 1614 out of 16216
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Dechra Pharmaceuticals Plc |
14.3
Low
|
19 out of 921 |
H. Lundbeck A/S |
19.3
Low
|
86 out of 921 |
GlaxoSmithKline Pharmaceuticals Ltd. |
22.1
Medium
|
137 out of 921 |
Organon & Co. |
23.3
Medium
|
168 out of 921 |
Hikma Pharmaceuticals Plc |
23.7
Medium
|
175 out of 921 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Dechra Pharmaceuticals Plc's Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Dechra Pharmaceuticals Plc's Management of ESG Material Risk is Strong
How do the ESG Risk Ratings work?
Top Material ESG Issues for Dechra Pharmaceuticals Plc
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Dechra Pharmaceuticals Plc's ESG Risk Rating in the last three years
Highest Controversy Level